The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) is a huge mover today! About 321,390 shares traded hands. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 11.64% since April 21, 2016 and is uptrending. It has outperformed by 6.31% the S&P500.
The move comes after 8 months positive chart setup for the $602.84 million company. It was reported on Nov, 23 by Barchart.com. We have $6.32 PT which if reached, will make NASDAQ:KERX worth $30.14 million more.
Analysts await Keryx Biopharmaceuticals (NASDAQ:KERX) to report earnings on February, 23. They expect $-0.22 earnings per share, up 38.89% or $0.14 from last year’s $-0.36 per share. After $-0.39 actual earnings per share reported by Keryx Biopharmaceuticals for the previous quarter, Wall Street now forecasts -43.59% EPS growth.
Keryx Biopharmaceuticals (NASDAQ:KERX) Ratings Coverage
Out of 14 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 rate it a “Buy”, 2 “Sell”, while 6 “Hold”. This means 43% are positive. Keryx Biopharmaceuticals has been the topic of 29 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The stock has “Sell” rating given by Zacks on Friday, August 28. On Monday, August 10 the stock rating was downgraded by Roth Capital to “Buy”. The company was initiated on Thursday, August 13 by Morgan Stanley. As per Tuesday, August 11, the company rating was initiated by FBR Capital. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Market Perform” rating by Raymond James on Wednesday, September 9. The rating was maintained by Raymond James on Tuesday, August 2 with “Outperform”. Maxim Group maintained Keryx Biopharmaceuticals (NASDAQ:KERX) rating on Tuesday, March 29. Maxim Group has “Buy” rating and $7 price target. As per Friday, July 8, the company rating was maintained by Maxim Group. The firm has “Market Perform” rating by Cowen & Co given on Thursday, July 23. As per Friday, February 26, the company rating was upgraded by Raymond James.
According to Zacks Investment Research, “Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.”
Insitutional Activity: The institutional sentiment increased to 1.07 in Q2 2016. Its up 0.58, from 0.49 in 2016Q1. The ratio improved, as 29 funds sold all Keryx Biopharmaceuticals shares owned while 43 reduced positions. 12 funds bought stakes while 23 increased positions. They now own 64.01 million shares or 1.49% less from 64.98 million shares in 2016Q1.
Gemmer Asset Mngmt Ltd Llc has invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). Oppenheimer And Com has 62,316 shares for 0.01% of their US portfolio. Blackrock Invest Lc has 296,076 shares for 0% of their US portfolio. Blackrock Advsrs Ltd accumulated 43,240 shares or 0% of the stock. Putnam Investments Ltd Llc holds 0.01% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX) for 675,702 shares. Wells Fargo And Mn accumulated 39,782 shares or 0% of the stock. Principal Fincl Group owns 13,893 shares or 0% of their US portfolio. Fmr Ltd Liability owns 3.17M shares or 0% of their US portfolio. The Georgia-based Ridgeworth Mgmt Lc has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Checchi Advisers holds 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX) for 16 shares. The Connecticut-based Trexquant L P has invested 0.02% in Keryx Biopharmaceuticals (NASDAQ:KERX). The Georgia-based Voya Limited Company has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). The Minnesota-based Ameriprise Financial has invested 0.01% in Keryx Biopharmaceuticals (NASDAQ:KERX). Clearbridge Investments Ltd Liability Corp reported 6,500 shares or 0% of all its holdings. Spot Trading Ltd Liability has 0.01% invested in the company for 65,343 shares.
Insider Transactions: Since July 5, 2016, the stock had 0 insider buys, and 11 selling transactions for $96,973 net activity. Neylan John F. also sold $5,716 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) shares. Another trade for 647 shares valued at $3,481 was made by Adams Brian on Wednesday, October 5. Another trade for 1,237 shares valued at $5,492 was sold by Holmes Scott A. Madison Greg had sold 917 shares worth $4,933 on Wednesday, October 5.
More notable recent Keryx Biopharmaceuticals (NASDAQ:KERX) news were published by: Fool.com which released: “Why Keryx Biopharmaceuticals Stock Jumped Today” on November 09, 2016, also Marketwatch.com with their article: “Keryx Biopharmaceuticals says kidney disease drug won’t be available until the …” published on August 01, 2016, Fool.com published: “What’s Behind Keryx Biopharmaceuticals’ 28.6% Jump in September?” on October 09, 2016. More interesting news about Keryx Biopharmaceuticals (NASDAQ:KERX) were released by: Reuters.com and their article: “BRIEF-Keryx Biopharmaceuticals files for mixed shelf of up to $250 million” published on November 09, 2016 as well as Globenewswire.com‘s news article titled: “Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at …” with publication date: November 18, 2016.
KERX Company Profile
Keryx Biopharmaceuticals, Inc., incorporated on October 22, 1998, is a biopharmaceutical company. The Firm is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Firm operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.